DNA-Responsive SiO2 Nanoparticles, Metal-Organic Frameworks, and Microcapsules for Controlled Drug Release
DNA-Responsive SiO2 Nanoparticles, Metal-Organic Frameworks, and Microcapsules for Controlled Drug Release
复制标题
DOI：
10.1021/acs.langmuir.8b00478
复制
发表时间：
2018-12-11
期刊：
影响因子：
3.9
通讯作者：
Willner, Itamar
中科院分区：
文献类型：
--
作者：
Vazquez-Gonzalez, Margarita;Willner, Itamar
介绍了用于药物控制释放的刺激响应性核酸（DNA）功能化微/纳米载体的最新进展。与载药载体相关的DNA充当将药物锁定在载体中的加帽单元。在存在适当的触发器的情况下，封盖单元被解锁，导致药物的释放。介绍了介孔SiO2纳米粒子、金属-有机骨架纳米粒子和微/纳米胶囊三种DNA修饰载体。解锁DNA门控单元的触发因素包括pH、在冠醚存在下K+稳定的G-四链体的解离、加帽单元通过酶或DNA酶的催化解离、加帽单元通过形成适体-配体复合物（特别是作为不同疾病的生物标志物的配体）的解离以及使用光来光化学解锁DNA门。讨论了不同载药载体对癌细胞的靶向作用、载药载体的开关释放以及载药载体对癌细胞的选择性细胞毒性等问题。最后，讨论了基于刺激响应性DNA的载药微/纳米载体用于未来纳米医学的未来前景，特别是自主感测和治疗系统的开发。
Recent advances addressing the development of stimuli-responsive nucleic acid (DNA)-functionalized micro/nanocarriers for the controlled release of drugs are presented. The DNA associated with the drug-loaded carriers acts as capping units that lock the drugs in the carriers. In the presence of appropriate triggers, the capping units are unlocked, resulting in the release of the drugs. Three types of DNA-modified carriers are discussed, including mesoporous SiO2 nanoparticles (MP SiO2 NPs), metal- organic framework nanoparticles (NMOFs) and micro/nanocapsules. The triggers to unlock the DNA gating units include pH, the dissociation of K+-stabilized G-quadruplexes in the presence of crown ethers, the catalytic dissociation of the capping units by enzymes or DNAzymes, the dissociation of capping units by the formation of aptamer-ligand complexes (particularly ligands acting as biomarkers for different diseases), and the use of light for the photochemical unlocking of the DNA gates. Different issues related to the targeting of the different drug-loaded carriers to cancer cells, the switchable ON/OFF release of the drug loads, and the selective cytotoxicity of the drug-loaded carriers toward cancer cells are discussed. Finally, the future perspectives of the stimuli-responsive DNA-based, drug-loaded micro/nanocarriers for future nanomedicine and, in particular, the development of autonomous sense-and-treat systems are addressed.